Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nexeon MedSystems Inc.

Latest From Nexeon MedSystems Inc.

Fed Up Of Poorly Run Academic Spin-Outs? Try This Instead

Three big pharma and three major UK universities are working together to "find, fund and run academic drug discovery projects at a pharma quality level." The collaboration has had a productive first year with four programs underway, two more about to be finalized, and "a good flow" in the pipeline, according to CEO Dr Richard Butt.

Companies Commercial

Puerto Rico Bolsters Its Life-Sciences Hub With R&D, Start-Up Initiatives

In the past year, Puerto Rico formed a consortium of clinical trial sites, launched a funding program for entrepreneurs and created a technology transfer office – all achievements touted at the Biolatam biotech conference in San Juan.

Medical Device Puerto Rico

Start-Up Quarterly Statistics, Q2 2010

Highlights from the Q2 2010 review of start-up dealmaking: Biopharma, medical device and in vitro diagnostics startups raised a total of $606 million, an 83% hike from the previous quarter but a 30% drop from Q2 2009. Unlike Q1, which saw four spin-offs, Q2 had just one. Three acquisitions closed including J&J's purchase of respiratory-focused RespiVert. During the second quarter of 2010, several companies signed multiple agreements including Clovis Oncology.

BioPharmaceutical Medical Device

The Future of Drug-Eluting Stents Part I: Novel Next-Generation Designs

Growth by innovation is almost considered a birthright in interventional cardiology, and based on presentations at this year's Transcatheter Cardiovascular Therapeutics meeting, held this September in San Francisco, it seems clear that innovation still reigns supreme in this specialty. However, as in other medical device markets, ongoing economic and regulatory pressures are taking their toll, particularly in the drug-eluting stent market, as the field adjusts to a new era of cost control and economic uncertainty.

Medical Device
See All

Company Information

  • Industry
  • Medical Devices
  • Other Names / Subsidiaries
    • Paragon Intellectual Properties LLC
    • Nexeon Medsystems Europe, SARL
    • Nexeon Medsystems Puerto Rico Operating Company Corporation
    • Pulsus Medical LLC